• Before any new drug or diagnostic technology can be used widely, it must pass through a series of structured studies designed to answer specific questions.
• The milestone highlighted in Quantum BioPharma’s announcement is that patient enrollment in a key pilot study has reached its halfway mark.
• Preliminary analyses show a robust signal in acute MS lesions, along with potential sensitivity to gray matter lesions.

LOS ANGELES, CA - June 29, 2026 (NEWMEDIAWIRE) - Clinical studies are among the most demanding and consequential undertakings in medicine. They require years of planning, careful patient selection, rigorous data collection and ongoing regulatory oversight, all in pursuit of a single goal - generating reliable evidence that a new drug, device or diagnostic tool is both safe and effective. Without this structured process, promising laboratory discoveries would never make the leap to treatments that physicians can confidently prescribe and patients can trust. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, recently announced in its collaborative imaging study with Massachusetts General Hospital (“MGH”) that the study has reached the halfway point in patient enrollment and early imaging results could support development of its multiple sclerosis drug candidate: Lucid-MS.

Studies of this kind sit at the center of how medicine advances. Before any new drug or diagnostic technology can be used widely, it must pass through a series of structured studies designed to answer specific questions: Does the approach work as intended? Is it safe? And can it reliably detect or…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law

This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Quantum BioPharma (QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study.